This is also the case for plasma insulin levels in humans where a mixed liquid meal is a stronger stimulus than oral glucose alone
as initiated) analyses, initiation of a GLP-1 receptor agonist was associated with a reduced risk of several incident SUDs (fig 3, fig 4, and supplementary table S6), including disorders related to alcohol use (hazard ratio 0.82 (95% CI 0.78 to 0.85), NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioids use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55))
Coverage is more likely when: You have a diagnosed deficiency: blood work shows your B12 level is below the standard range
It is important to note that most concerns about nutrient status with GLP-1 therapy relate to reduced dietary intake rather than direct malabsorption
Let's explore packaging considerations to ensure maximum potency retention